Intensity Therapeutics, Inc. Common stock

Stock Chart, Company Information, and Scan Results

$0.27(as of Oct 20, 12:29 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Intensity Therapeutics, Inc. Common stock Company Information, Fundamentals, and Technical Indicators

Stock Price$0.27
Ticker SymbolINTS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees5
CountyUSA
Market Cap$12.8M

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Intensity Therapeutics, Inc. Common stock In Our Stock Scanner

As of Oct 20, 2025
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.